Evidence map›Paper›PMID 37460640›Full record

ArticleNature immunology2023

Stem-cell-like CD4

Joshua R Veatch, Stanley R Riddell

Abstract readComment
PubMed Publisher
In one paragraph

Article in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Joshua R VeatchTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Stanley R RiddellTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. sriddell@fredhutch.org.ORCID http://orcid.org/0000-0002-4688-9920
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAFred Hutch Cancer Center · US

Funding

Project 4: Risk stratification for pulmonary nodules detected by CT imaging using plasma and imaging biomarkersP50CA228944 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI David MacPherson · 2019 to 2026
$19.6M
TARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLSR01CA114536 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Sylvain Simon · 2005 to 2026
$8.4M
NCI NIH HHS P50 CA228944NCI NIH HHS R01 CA114536
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Genes, MHC Class IINeoplasmsCD4-Positive T-LymphocytesHistocompatibility Antigens Class IIHumansHistocompatibility Antigens Class II

Identifiers

PMID37460640
OpenAlexW4384522302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.